Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission

Journal of Theoretical Biology

Volumn 395, Issue , 2016, Pages 31-39

  Rozada, Ignacio ^a   Coombs, Daniel ^b   Lima, Viviane D ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Basic reproduction number; Fibrosis; HCV; Mathematical model; Stability

Indexed keywords

DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG; HEPATITIS; INFECTIOUS DISEASE; NUMERICAL MODEL;

ARTICLE; CALIBRATION; CANADA; CLINICAL PRACTICE; COMPUTER SIMULATION; DETERMINISTIC COMPARTMENTAL MODEL; DISEASE COURSE; DISEASE ERADICATION; FIBROSIS AWARE MODEL; HEALTH CARE ACCESS; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; LIVER FIBROSIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MISCELLANEOUS NAMED GROUPS; MORTALITY; NUMERICAL SIMULATION; PEOPLE WHO INJECT DRUG; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; TIME TO TREATMENT; VIRUS TRANSMISSION; BIOLOGICAL MODEL; FEMALE; LIVER CIRRHOSIS; MALE; SUBSTANCE-RELATED DISORDERS; TRANSMISSION;

BRITISH COLUMBIA; CANADA; VANCOUVER [BRITISH COLUMBIA];

HEPATITIS C VIRUS;

FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MODELS, BIOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 84957990678     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2016.01.030     Document Type: Article

References (42)

1. Alavi M., Raffa J.D., Deans G.D., Lai C., Krajden M., Dore G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2013, 34(8):1198-1206.
2. Anderson R.M., May R.M., et al. Population biology of infectious diseases. part I. Nature 1979, 280(5721):361-367.
3. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996, 24(2):289-293.
4. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005, 40:S336-S338.
5. Diekmann O., Heesterbeek J., Roberts M. The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface 2009, 873-885.
6. Diekmann O., Heesterbeek H., Britton T. Mathematical Tools for Understanding Infectious Disease Dynamics 2012, Princeton University Press, Oxford and Princeton, NJ.
7. Elbasha E.H. Model for hepatitis C virus transmissions. Math. Biosci. Eng. 2013, 10:4. 10.3934/mbe.2013.10.1045.
8. Feeney E.R., Chung R.T., et al. Antiviral treatment of hepatitis C. Br. Med. J. 2014, 349:g3308.
9. George S.L., Bacon B.R., Brunt E.M., Mihindukulasuriya K.L., Hoffmann J., Di Bisceglie A.M. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy. a 5-year follow-up of 150 patients. Hepatology 2009, 49(3):729-738.
10. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J. Viral Hepat. 2009, 16(5):352-358.
11. Grebely J., Knight E., Ngai T., Genoway K.A., Raffa J.D., Storms M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J. Gastroenterol. Hepatol. 2010, 25(7):1281-1284.
12. Grebely J., Matthews G.V., Lloyd A.R., Dore G.J. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin. Infect. Dis. 2013, 57(7):1014-1020.
13. Grebely J., Page K., Sacks-Davis R., Loeff M.S., Rice T.M., Bruneau J., et al. The effects of female sex, viral genotype, and il28b genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014, 59(1):109-120.
14. Grebely J., Lima V.D., Marshall B.D., Milloy M., DeBeck K., Montaner J., et al. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLoS ONE 2014, 9(6):e97726.
15. Hajarizadeh, B., Grady, B., Page, K., Kim, A., McGovern, B., Cox, A., et al., 2015. Factors associated with hepatitis c virus rna levels in early chronic infection: the inc3 study. J. Viral Hepat.
16. Hézode C., Fontaine H., Dorival C., Larrey D., Zoulim F., Canva V., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J. Hepatol. 2013, 59(3):434-441.
17. Hull M., Klein M., Shafran S., Tseng A., Giguere P., Cote P., et al. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core. Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can. J. Infect. Dis. Med. Microbiol. (Journal Canadien des Maladies Infectieuses et de la Microbiologie Medicale/AMMI Canada) 2012, 24(4):217-238.
18. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. J. Viral Hepat. 2014, 21(3):198-207.
19. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., et al. Treatment of acute hepatitis C with interferon alfa-2b. New Engl. J. Med. 2001, 345(20):1452-1457.
20. Jones, E., Oliphant, T., Peterson, P., et al., 2001. SciPy: Open Source Scientific Tools for Python. URL 〈〉. http://www.scipy.org/.
21. Keller H.B. Lectures on Numerical Methods in Bifurcation Theory. Tata Institute of Fundamental Research Lectures on Mathematics and Physics 1987, Springer-Verlag, New York.
22. Kleinman S.H., Lelie N., Busch M.P. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009, 49(11):2454-2489. 10.1111/j.1537-2995.2009.02322.x.
23. Kwon J.A, Iversen J., Maher L., Law M.G., Wilson D.P. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia. a model-based analysis (1999). J. Acquir. Immune Defic. Syndr. 2009, 51(4):462-469. 10.1097/QAI.0b013e3181a2539a.
24. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009, 29(s1):74-81.
25. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New Engl. J. Med. 2013, 368(20):1878-1887.
26. Lima V.D., Rozada I., Grebely J., Hull M., Lourenco L., Nosyk B., et al. Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs?. PLoS ONE 2015, 10(12):e0143836.
27. Ly K.N., Xing J., Klevens R.M., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Internal Med. 2012, 156(4):271-278.
28. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis b. a 5-year open-label follow-up study. Lancet 2013, 381(9865):468-475.
29. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs. modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58(5):1598-1609.
30. Micallef J., Kaldor J., Dore G. Spontaneous viral clearance following acute hepatitis C infection. a systematic review of longitudinal studies. J. Viral Hepat. 2006, 13(1):34-41.
31. Mondelli M.U., Cerino A., Cividini A. Acute hepatitis C. diagnosis and management. J. Hepatol. 2005, 42(1):S108-S114.
32. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs. results of systematic reviews. Lancet 2011, 378(9791):571-583.
33. Puri N., DeBeck K., Feng C., Kerr T., Rieb L., Wood E. Gender influences on hepatitis C incidence among street youth in a Canadian setting. J. Adolesc. Health 2014, 55(6):830-834.
34. Razavi H., Waked I., Sarrazin C., Myers R., Idilman R., Calinas F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J. Viral Hepat. 2014, 21(s1):34-59.
35. Remis, R.S., 2010. Modelling the Incidence and Prevalence of Hepatitis C Infection and Its Sequelae in Canada, 2007. Public Health Agency of Canada website.
36. Rossum, G., 1995. Python Reference Manual. Technical Report, CWI (Centre for Mathematics and Computer Science), Amsterdam, The Netherlands.
37. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Internal Med. 2000, 132(7):517-524.
38. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection. a meta-analysis and meta-regression. Hepatology 2008, 48(2):418-431.
39. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users. pooling of UK evidence. Addiction 2011, 106(11):1978-1988.
40. UHRI, 2013. Drug situation in Vancouver. Available from the BC Centre for Excellence in HIV/AIDS website:. 2013. URL 〈〉. http://www.cfenet.ubc.ca/sites/default/files/uploads/news/releases/war_on_drugs_failing_to_limit_drug_use.pdf.
41. Van den Driessche P., Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 2002, 180(1):29-48.
42. Yu A., Spinelli J.J., Cook D.A., Buxton J.A., Krajden M. Mortality among British Columbians testing for hepatitis C antibody. BMC Public Health 2013, 13(1):291. 10.1186/1471-2458-13-291.